Overview
Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
Status:
Completed
Completed
Trial end date:
2005-12-01
2005-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this study was to investigate the bioequivalence of Mylan's olmesartan medoxomil 40 mg tablets to Sankyo's Benicar® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose administered under fasting conditions.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Mylan PharmaceuticalsTreatments:
Olmesartan
Olmesartan Medoxomil
Criteria
Inclusion Criteria:- healthy, adult subjects, 18 years and older
- able to swallow medication
Exclusion Criteria:
- institutionalized subjects
- history of any significant disease
- use of any prescription or OTC medications within 14 days of start of study
- received any investigational products within 30 days prior to start of study